Scholarlink

Background <p>The determination of the β‑subunit of human chorionic gonadotropin (HCG) is routinely used in urology as a&#xa0;tumor marker for germ cell tumors. This review highlights the differential diagnoses of β‑HCG elevation unrelated to germ cell cancer.</p> Results <p>Causes of elevated β‑HCG levels include, among others, measurement errors due to the homology between luteinizing hormone (LH) and β‑HCG or in cases of immunoglobulin&#xa0;A (IgA) deficiency syndrome, reduced excretion in renal insufficiency, iatrogenic causes (e.g., substitution therapy, during androgen deprivation therapy), or hormonal disorders. Additionally, β‑HCG is produced autocrinely by 10–30% of all malignant nongerm cell tumors. In urothelial carcinoma, literature reports show positive detection in 30–76% of serum samples, 35–73% of urine samples, and approximately 35% in immunohistochemical analyses. Apart from testicular tumors, β‑HCG currently has no established role in routine tumor diagnostics. The expression pattern in the metastatic stage of urothelial carcinoma correlates with therapeutic response.</p> Conclusion <p>In cases of implausible β‑HCG elevation during testicular tumor diagnostics or follow-up, one must consider the numerous differential diagnoses. In the future, β‑HCG could become a&#xa0;promising marker for monitoring hormone-expressing, metastatic urothelial carcinoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Erhöhung der β-Untereinheit des humanen Choriongonadotropins bei urologischen Patienten – nicht immer ein Keimzelltumor

  • 期刊论文

  • 发表日期：

    2025年9月16日

查看全文
  • Luisa Witte,
  • Matthäus Majewski

摘要

Background

The determination of the β‑subunit of human chorionic gonadotropin (HCG) is routinely used in urology as a tumor marker for germ cell tumors. This review highlights the differential diagnoses of β‑HCG elevation unrelated to germ cell cancer.

Results

Causes of elevated β‑HCG levels include, among others, measurement errors due to the homology between luteinizing hormone (LH) and β‑HCG or in cases of immunoglobulin A (IgA) deficiency syndrome, reduced excretion in renal insufficiency, iatrogenic causes (e.g., substitution therapy, during androgen deprivation therapy), or hormonal disorders. Additionally, β‑HCG is produced autocrinely by 10–30% of all malignant nongerm cell tumors. In urothelial carcinoma, literature reports show positive detection in 30–76% of serum samples, 35–73% of urine samples, and approximately 35% in immunohistochemical analyses. Apart from testicular tumors, β‑HCG currently has no established role in routine tumor diagnostics. The expression pattern in the metastatic stage of urothelial carcinoma correlates with therapeutic response.

Conclusion

In cases of implausible β‑HCG elevation during testicular tumor diagnostics or follow-up, one must consider the numerous differential diagnoses. In the future, β‑HCG could become a promising marker for monitoring hormone-expressing, metastatic urothelial carcinoma.